HK Stock MarketDetailed Quotes

01875 TOT BIOPHARM-B

Watchlist
  • 1.890
  • -0.030-1.56%
Market Closed Sep 13 16:08 CST
1.46BMarket Cap145.38P/E (TTM)

TOT BIOPHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
Turnover
58.69%520.6M
67.79%222.54M
76.54%780.63M
77.25%541.98M
80.24%328.06M
65.28%132.63M
479.34%442.18M
744.11%305.78M
686.87%182.02M
450.25%80.25M
Operating income
58.69%520.6M
76.54%780.63M
80.24%328.06M
479.34%442.18M
686.87%182.02M
Cost of sales
-84.08%-143.7M
----
-188.76%-206.64M
----
-232.48%-78.06M
----
-46.49%-71.56M
----
-156.79%-23.48M
----
Operating expenses
-84.08%-143.7M
-188.76%-206.64M
-232.48%-78.06M
-46.49%-71.56M
-156.79%-23.48M
Gross profit
50.76%376.91M
54.87%573.99M
57.69%250M
1,248.97%370.62M
1,033.33%158.54M
Selling expenses
-40.08%-276.48M
----
-116.23%-441.02M
----
-181.60%-197.38M
----
-792.62%-203.95M
----
-525.70%-70.09M
----
Administrative expenses
-3.22%-32.11M
----
-9.14%-68.31M
----
-21.04%-31.1M
----
-11.10%-62.59M
----
4.19%-25.7M
----
Research and development expenses
7.82%-46.06M
----
31.28%-103.89M
----
28.89%-49.97M
----
29.59%-151.17M
----
20.82%-70.27M
----
Impairment and provision
1,868.96%9.45M
----
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
----
-Other impairment is provision
1,868.96%9.45M
----
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
----
Special items of operating profit
-88.46%1.55M
----
104.92%17.65M
----
798.05%13.39M
----
28.39%8.62M
----
156.05%1.49M
----
Operating profit
328.17%33.26M
15.40%-33.06M
-109.79%-14.58M
84.95%-39.08M
93.98%-6.95M
Financing income
70.74%2.18M
----
31.30%2.97M
----
207.95%1.28M
----
133.75%2.27M
----
-41.88%415K
----
Financing cost
-71.65%-3.88M
----
21.61%-5.18M
----
33.85%-2.26M
----
-167.50%-6.6M
----
-1,147.45%-3.42M
----
Share of profit from joint venture company
----
----
62.39%-2.5M
----
106.88%397K
----
-38,917.65%-6.63M
----
---5.77M
----
Earning before tax
308.15%31.56M
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
Tax
----
----
---1K
----
---1K
----
----
----
----
----
After-tax profit from continuing operations
308.13%31.56M
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
Earning after tax
308.13%31.56M
145.24%7.41M
24.56%-37.76M
22.28%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.84%-50.05M
76.57%-41.68M
86.33%-15.72M
88.97%-4.71M
Minority profit
----
----
----
----
----
----
---130K
----
----
----
Profit attributable to shareholders
308.13%31.56M
145.24%7.41M
24.36%-37.76M
20.10%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.89%-49.92M
77.21%-40.54M
86.33%-15.72M
-4.71M
Basic earnings per share
300.00%0.04
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
Diluted earnings per share
300.00%0.04
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Auditor
--
--
PricewaterhouseCoopers
--
--
--
PricewaterhouseCoopers
--
--
--
(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022
Turnover 58.69%520.6M67.79%222.54M76.54%780.63M77.25%541.98M80.24%328.06M65.28%132.63M479.34%442.18M744.11%305.78M686.87%182.02M450.25%80.25M
Operating income 58.69%520.6M76.54%780.63M80.24%328.06M479.34%442.18M686.87%182.02M
Cost of sales -84.08%-143.7M-----188.76%-206.64M-----232.48%-78.06M-----46.49%-71.56M-----156.79%-23.48M----
Operating expenses -84.08%-143.7M-188.76%-206.64M-232.48%-78.06M-46.49%-71.56M-156.79%-23.48M
Gross profit 50.76%376.91M54.87%573.99M57.69%250M1,248.97%370.62M1,033.33%158.54M
Selling expenses -40.08%-276.48M-----116.23%-441.02M-----181.60%-197.38M-----792.62%-203.95M-----525.70%-70.09M----
Administrative expenses -3.22%-32.11M-----9.14%-68.31M-----21.04%-31.1M-----11.10%-62.59M----4.19%-25.7M----
Research and development expenses 7.82%-46.06M----31.28%-103.89M----28.89%-49.97M----29.59%-151.17M----20.82%-70.27M----
Impairment and provision 1,868.96%9.45M-----1,823.12%-11.48M----152.00%480K-------597K-------923K----
-Other impairment is provision 1,868.96%9.45M-----1,823.12%-11.48M----152.00%480K-------597K-------923K----
Special items of operating profit -88.46%1.55M----104.92%17.65M----798.05%13.39M----28.39%8.62M----156.05%1.49M----
Operating profit 328.17%33.26M15.40%-33.06M-109.79%-14.58M84.95%-39.08M93.98%-6.95M
Financing income 70.74%2.18M----31.30%2.97M----207.95%1.28M----133.75%2.27M-----41.88%415K----
Financing cost -71.65%-3.88M----21.61%-5.18M----33.85%-2.26M-----167.50%-6.6M-----1,147.45%-3.42M----
Share of profit from joint venture company --------62.39%-2.5M----106.88%397K-----38,917.65%-6.63M-------5.77M----
Earning before tax 308.15%31.56M24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M
Tax -----------1K-------1K--------------------
After-tax profit from continuing operations 308.13%31.56M24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M
Earning after tax 308.13%31.56M145.24%7.41M24.56%-37.76M22.28%-32.39M3.57%-15.16M-247.46%-16.38M80.84%-50.05M76.57%-41.68M86.33%-15.72M88.97%-4.71M
Minority profit ---------------------------130K------------
Profit attributable to shareholders 308.13%31.56M145.24%7.41M24.36%-37.76M20.10%-32.39M3.57%-15.16M-247.46%-16.38M80.89%-49.92M77.21%-40.54M86.33%-15.72M-4.71M
Basic earnings per share 300.00%0.0437.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.03
Diluted earnings per share 300.00%0.0437.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.03
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions ----Unqualified Opinion------Unqualified Opinion------
Auditor ----PricewaterhouseCoopers------PricewaterhouseCoopers------

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data